Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose

Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?

CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools including Health100 and Claims Assist Manager to improve efficiency and customer service. However, reimbursement pressure, regulatory scrutiny, and insufficient Medicare Advantage payment updates remain key headwinds. With a discounted valuation (P/S of 0.29X vs. industry average 0.53X), Zacks recommends current holders maintain positions while prospective investors wait for a more favorable entry point.

BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?

BrightSpring Health Services (BTSG) reported strong Q2 2026 results with Specialty and Infusion revenue growing 30% and scripts rising 31%, driven by branded limited distribution drugs (LDDs) and expansion into rare and orphan therapies. The company added two new LDDs, bringing its portfolio to 155 programs with 12 launched in 2026. Pharmacy Solutions adjusted EBITDA increased 44% to $180 million. Peers Cigna and Humana also showed strength in specialty pharmacy segments, though with different growth drivers.

FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.

'Vance-Led Task Force Set to Remove 760,000 Allegedly Fraudulent Obamacare Enrollments' - WSJ Exclusive

https://www.wsj.com/politics/policy/vance-led-task-force-set-to-remove-760-000-allegedly-fraudulent-obamacare-enrollments-0fbb72d7

CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

CVS Health stock declined 1.4% to $87.60, underperforming the broader market which gained 1.49%. The stock has fallen 4.49% over the past month. The company is expected to report flat EPS of $1.6 for the upcoming quarter with revenue projected at $105.04 billion (up 2.11% YoY). CVS holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 11.07, below its industry average of 17.31.